MedTrace Logo

Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults

NCT04472650 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2024-10-26

Study results available
· View outcomes & findings →

Summary

The primary objective of the study was to investigate the relative bioavailability and pharmacokinetics (PK) of sitravatinib free base and malate salt capsule formulations following oral administration in healthy adults.

Conditions

  • Tumor

Interventions

DRUG

Sitravatinib

Administered orally as a free base capsule

DRUG

Sitravatinib

Administered orally as a malate salt capsule

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Study Director · BeiGene

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-23
Primary Completion
2020-11-09
Completion
2020-11-09
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04472650 on ClinicalTrials.gov